AME

AMETEK is a textbook high-quality compounder and FY2025 was a record year on every line the company tracks: net sales $7.40B (+6.6%), net income $1.48B (+7.6%), diluted EPS $6.40 (+7.9%), record orders of $7.58B (+11.3%) and a record $3.58B backlog. Profitability is excellent and durable — 25.8% operating margin, 20.0% net margin — and the balance sheet is conservative at just 0.51x liabilities/equity with $12.3B of retained earnings and growing equity (+10.1%). Free cash flow of $1.67B comfortably funds the $285M dividend (+10.3%) and $443M of buybacks (the company repurchased ~2.3M shares, more than double 2024's pace), and the 'AMETEK Growth Model' M&A engine added Kern and FARO for $933M in 2025. This is a business you want to own.

The caution is entirely about price and the composition of growth. At $237.42 the stock trades at 37.1x EPS and 7.3x sales, a PEG north of 4 against high-single-digit EPS growth — the multiple already discounts continued flawless execution. Crucially, the MD&A shows the 6.6% sales gain was 4% from acquisitions and 1% from FX, leaving only ~2% organic. So AMETEK is buying much of its growth, which shows up in a merely-good 13.9% ROE (goodwill-heavy equity) and rising near-term obligations: current debt jumped +84.8% to $1.21B and current liabilities +35.5% to $2.84B, thinning the current ratio to ~1.06x against just $458M of cash. None of this is alarming for a cash machine of this caliber, but it caps the margin of safety.